Evaluations of primary lesions by endoscopy clearly distinguishes prognosis in patients with gastric cancer who receive chemotherapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluations of primary lesions by endoscopy clearly distinguishes prognosis in patients with gastric cancer who receive chemotherapy
Authors
Keywords
-
Journal
PLoS One
Volume 12, Issue 3, Pages e0173663
Publisher
Public Library of Science (PLoS)
Online
2017-03-14
DOI
10.1371/journal.pone.0173663
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker
- (2013) Masahiro Hirakawa et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer
- (2013) Akira Tsuburaya et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis
- (2013) Ulrike Heger et al. Gastric Cancer
- Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy
- (2013) Takaki Yoshikawa et al. SURGERY TODAY
- Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry
- (2012) Atsushi Nashimoto et al. Gastric Cancer
- Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
- (2012) Kensei Yamaguchi et al. Gastric Cancer
- A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)
- (2011) Wasaburo Koizumi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial)
- (2011) Tetsuya Hamaguchi et al. Gastric Cancer
- Japanese classification of gastric carcinoma: 3rd English edition
- (2011) Gastric Cancer
- Clinical significance of evaluating primary lesions in patients with gastric cancer who receive chemotherapy
- (2010) Kento Nakatani et al. Gastric Cancer
- A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703)
- (2010) Yasuhiro Kodera et al. Gastric Cancer
- Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
- (2009) A. F. C. Okines et al. ANNALS OF ONCOLOGY
- Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
- (2009) Narikazu Boku et al. LANCET ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started